28th Apr 2016 11:11
LONDON (Alliance News) - Summit Therapeutics PLC Thursday said it has been granted a further US patent for its Clostridium difficile infection antibiotic ridinilazole.
The patent provides a period of exclusivity for ridinilazole in the US until at least the beginning of December 2029, Summit said.
"This new patent grant in one of our potential major commercial markets substantially strengthens our intellectual property estate protecting our novel CDI antibiotic ridinilazole and supports our efforts to maximise the potential of this promising compound," said Chief Executive Glyn Edwards in a statement.
Shares in Summit Therapeutics were up 1.5% at 132.49 pence Thursday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
SUMM.L